Clinical Leadership with Cue Biopharma's Anish Suri, Ph.D. & Dan Passeri, J.D.

We love to hear from our listeners. Send us a message. On a road trip to Boston, the Business of Biotech caught up with podcast alum Dan Passeri, J.D., CEO at Cue Biopharma, and enjoyed a two-for-one with CSO & President Anish Suri, Ph.D. at Cue's headquarters just feet below the Auerbach Center. Among other things, we discussed the duo's complementary leadership approach as the company takes multiple candidates into the clinic, why Passeri leans into his biotech legal background almost every day he's at work, the successful navigation of outsourced manufacturing relationships, why Cue's discretely targeted IL-2 approach eliminates the absurdity of early IL-2 failures, and a whole lot more. Speaking of Dan's legal background, before you jump into today'sepisode, REGISTER for the first-ever, interactive Business of Biotech Live! Legal & IPProtection For New Biotechs here!Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/